GlassScriptPhysician profile
Mark Edward Gentry
NPI 1144260191
$3,104.61
in general payments reported to CMS, 2019-2025
33 companies · $490 in 2025
The $490 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $185 · 2021: $341 · 2022: $410 · 2023: $690 · 2024: $353 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $622.36 | 2019-2023 | |
| Novo Nordisk INC | $347.04 | 2019-2024 | Wegovy |
| Sumitomo Pharma America, INC. | $278.55 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $208.65 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $201.16 | 2022-2025 | |
| Minerva Surgical, INC | $168.74 | 2019-2025 | |
| Coopersurgical, INC. | $157.02 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $156.72 | 2021-2023 | |
| Therapeuticsmd, INC. | $115.50 | 2020-2022 | |
| Exact Sciences Corporation | $99.92 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Exeltis, USA INC. | $88.06 | 2021-2025 | Slynd |
| Biogen, INC. | $83.83 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $71.67 | 2021-2022 | |
| Daiichi Sankyo INC. | $67.43 | 2019 | |
| Hologic Sales and Service, LLC | $58.74 | 2019-2025 | Fluent Fluid Management System, Novasure, Myosure Tissue Removal Device |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $48.16 | 2025 | Intrarosa, Femlyv |
| Shield Therapeutics INC | $40.90 | 2024-2025 | |
| Duchesnay USA Incorporated | $39.59 | 2019 | |
| Amag Pharmaceuticals, INC. | $27.76 | 2019-2020 | |
| Roche Diagnostics Corporation | $24.34 | 2019 | |
| Agile Therapeutics, INC. | $21.85 | 2022 | |
| Medtronic, INC. | $21.46 | 2021 | |
| Axonics, INC. | $20.66 | 2023 | Axonics |
| Evofem Biosciences, INC. | $18.81 | 2022 | |
| Merck Sharp & Dohme LLC | $15.33 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.69 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.55 | 2020 | |
| Meditrina | $13.56 | 2023 | |
| Lupin INC. | $12.11 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.62 | 2019 | |
| Allergan, INC. | $11.43 | 2019 | |
| Organon LLC | $11.38 | 2021 | |
| Asensus Surgical, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.